Harmony Biosciences Holdings Inc (NASDAQ: HRMY) is a pharmaceutical company that develops and commercializes treatments for patients living with rare and other neurological diseases. The company generates revenue through prescription drug sales, with its commercial products sold to patients via the U.S. healthcare system. The filing confirms HRMY is listed on the Nasdaq Global Market. The provided 10-K excerpts (filed 2026-02-24, accession 000110465926018859) do not contain sufficient detail to specify revenue figures, product names, market share, competitive positioning, founding year, CEO tenure, customer concentration, or geographic breakdown beyond a U.S. commercial presence implied by the filing structure. Only facts directly supported by the excerpts are included here; additional detail will require full 10-K body text.

Revenue model

The filing excerpts do not provide sufficient detail to describe the revenue model with specific figures or product-level breakdown.

Products and services

The filing excerpts do not name specific products or brands.

Customers and end markets

The filing excerpts reference neurological disease patients and industry markets but do not provide specific customer counts, concentration data, or end-market revenue splits.

Value-chain role

Commercial-stage pharmaceutical company operating in drug development and commercialization.

Geographic exposure

The filing excerpts do not provide a geographic revenue breakdown.

Source: SEC 10-K, filed 2026-02-24

Industry: Pharmaceutical Preparations Peers: Arvinas Inc Pacira Biosciences Inc CORCEPT THERAPEUTICS INC Elanco Animal Health Inc Intra-Cellular Therapies, Inc. Johnson & Johnson Organon & Co Prestige Consumer Healthcare Inc